Skip to main content

PanTera signs agreement with Bayer for the supply of actinium-225

13 February '24

Agreement demonstrates PanTera’s unique ability to support the radionuclide therapeutics industry in bringing new cancer treatments to patients

PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of alpha-emitting radioisotopes, today announces the signing of a capacity reservation agreement with Bayer for the supply of actinium-225 (225Ac) starting in the second half of 2024.

SCK  CEN  -  Lancering Pantera (2022)

This first agreement with a major drug developer reflects PanTera’s unique position to be a reliable, EU-based supplier of 225Ac from this year onward. In 2024, PanTera will continue to work on increasing access to 225Ac for clinical trial needs, as well as on the development of a large-scale, state-of-the-art production facility to address growing global demand.

Sven Van den Berghe, CEO of PanTera, commented, “PanTera’s emerging ability to start supplying 225Ac this year will allow research and clinical trials in this domain to advance. The combined expertise and technology from SCK CEN and IBA places PanTera in a unique position to become the go-to global supplier of 225Ac for (pre-)clinical trials and commercial use. PanTera is committed to supporting the pharmaceutical industry by scaling up production to meet the significant global demand for targeted radiopharma-based therapeutics in the fight against cancer.”

Want to know more about PanTera? Then, pay a visit to the website.

Click here

Share this news article